Welcome to our dedicated page for Rxsight news (Ticker: RXST), a resource for investors and traders seeking the latest updates and insights on Rxsight stock.
RxSight, Inc. develops and sells ophthalmic medical technology for customized vision after cataract surgery. Its RxSight Light Adjustable Lens system includes Light Adjustable Lens products, the Light Delivery Device and related accessories, enabling post-operative adjustment of an intraocular lens based on patient visual feedback.
RxSight news commonly covers financial results, sales guidance, Light Adjustable Lens unit demand, Light Delivery Device placements and installed-base growth. Company updates also address clinical evidence presented in cataract and refractive surgery forums, regulatory approvals in international markets, healthcare conference participation and executive finance leadership changes.
RxSight (NASDAQ: RXST) reported Q2 2026 revenue of $33.7 million, essentially flat year over year, including $6.5 million from its new strategic collaboration with Alcon. Product sales were $27.2 million, down 19%, with 24,917 Light Adjustable Lens units and 12 Light Delivery Devices sold.
Excluding collaboration revenue, gross margin was 71.2% versus 74.9% a year ago; including it, gross margin was 76.7%. Operating expenses were $39.7 million. Net loss was $12.1 million (basic and diluted $(0.29) per share). Adjusted net loss was $4.6 million, or $(0.11) per share. Cash, cash equivalents and short-term investments totaled $208.8 million on June 30, 2026.
RxSight appointed Aziz Mottiwala as President and CEO, entered a collaboration with Alcon that includes up to $200 million in upfront and milestone payments plus future royalties, and announced development of a next-generation Light Adjustable Technology platform. In connection with the leadership transition, the company withdrew its 2026 guidance and plans to resume formal guidance in early 2027.
RxSight (NASDAQ: RXST) reported that on July 24, 2026 it granted inducement equity awards to new President and CEO Aziz Mottiwala in connection with his employment. The awards include stock options for 571,286 shares at an exercise price of $5.19 and RSUs covering 2,312,138 shares.
The options vest 25% on the one-year anniversary of July 24, 2026, with the remainder vesting in equal monthly installments over the following three years. The RSUs vest 20% on each of the first two anniversaries and 60% on the third anniversary. The grants were made under the 2026 Inducement Equity Incentive Plan pursuant to Nasdaq Listing Rule 5635(c)(4).
RxSight (NASDAQ: RXST) announced a planned leadership transition effective July 20, 2026, appointing Aziz Mottiwala as President and Chief Executive Officer, succeeding Ron Kurtz, M.D., who will continue with the company as Chief Medical Officer.
According to RxSight, Mottiwala brings extensive commercial eye-care experience, including prior Chief Commercial Officer roles at Tarsus Pharmaceuticals and Opiant Pharmaceuticals and senior leadership positions at Allergan. Dr. Kurtz, recognized for his role in establishing adjustability in the ophthalmic marketplace, will focus on advancing RxSight’s technology, clinical value, and expansion of adjustability into broader market segments as CMO. As part of the transition, Dr. Kurtz will resign from the Board of Directors, and Mottiwala will be appointed to the Board. RxSight stated it is not updating its previously communicated financial guidance in connection with this announcement.
RxSight (NASDAQ: RXST) expects preliminary Q2 2026 revenue of $32–$34 million, including $5–$7 million from its Alcon collaboration. Product sales are about $27 million, with 24,917 LAL units and 11 LDD units sold, and cash of $209 million on June 30, 2026.
For 2026, revenue guidance is $140–$160 million, with sales of $110–$120 million (reduced from $120–$135 million) and collaboration revenue of $30–$40 million. Gross margin is guided to 73–75%, above prior 70–72%, and operating expenses are expected at the high end of $150–$160 million. The company also highlighted a next-generation Light Adjustable Technology platform, including new LAL, LAL+ and LAL Toric lenses, alongside its strategic collaboration with Alcon on light-adjustable presbyopia-correcting intraocular lenses.
Alcon (NYSE:ALC) and RxSight (NASDAQ:RXST) entered a non-exclusive license and development agreement to create adjustable presbyopia-correcting intraocular lenses (PCIOLs).
RxSight receives a $60 million upfront payment, up to $140 million in development and regulatory milestones, and royalties, while Alcon leads global commercialization and RxSight handles development and manufacturing.
RxSight (NASDAQ: RXST) will participate in the Stifel 2026 Virtual Ophthalmology Forum. Company management is scheduled for a fireside chat on Tuesday, May 26, 2026, at 10:00 a.m. Pacific Time.
A live and archived webcast will be accessible via RxSight’s investor relations website.
RxSight (NASDAQ: RXST) reported Q1 2026 revenue of $30.9 million, down 18.5% year‑over‑year, with 27,472 LAL units and 20 LDDs sold, expanding the installed base to 1,154 LDD units. Gross margin was 76.1%. Net loss was $15.9 million (−$0.38/share). Cash and short‑term investments totaled $217.9 million. 2026 guidance reiterated: revenue $120–$135 million, gross margin 70–72%, and operating expenses at the high end of the prior $150–$160 million range.
RxSight (NASDAQ:RXST) will present at the Bank of America Healthcare Conference on Wednesday, May 13, 2026 at 3:00 p.m. PT. Management will take part in a fireside chat. A live and archived webcast will be available on the company’s investor relations website.
RxSight (NASDAQ: RXST) will report first-quarter 2026 financial results on May 6, 2026 after market close.
Management will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET with dial-in numbers and a listen-only webcast on the company investor relations site; an archived recording will be posted after the call.
RxSight (NASDAQ: RXST) announced it has surpassed 300,000 Light Adjustable Lens (LAL) implants since launch and will feature 35 scientific presentations at ASCRS 2026.
Company highlights include published outcomes showing high refractive accuracy and a new surgeon-focused outreach program to expand patient access.